Image credit- shutterstock
Germany-based numares Health, the transformative metabolomics company pioneering multidimensional biomarker insights that deliver clinical pathways for optimal patient care, has announced the expansion of its global footprint into the ASEAN region having received regulatory approval in Malaysia and subsequently securing its first contract for the AXINON®LDLp Test System with BioD Medica, who specialise in introducing medical devices and healthcare technology into Malaysia and Singapore.
This is the first regulatory approval in the ASEAN region for the AXINON® LDLp Test System. Concurrently, numares has secured its first contract with BioD Medica, who specialise in introducing medical devices and healthcare technology into Malaysia and Singapore, providing healthcare professionals with accessible and innovative diagnostic devices to transform patient outcomes.
Cardiovascular diseases (CVDs) are the leading cause of death globally according to the World Health Organization. The most important biomarkers for determining CVD risk are lipids, including total cholesterol, triglycerides, LDL and HDL cholesterol. Studies show standard lipid profile tests do not capture all available information, whereas the AXINON® LDLp Test System measures the concentration, size and distribution of lipoprotein particles (LDL-p) – the particles that carry cholesterol – to provide a more accurate result, especially for people with comorbidities who are at higher risk for CVDs.
